MSR78 Use of External Control Data to Adjust for Treatment Switching in Cost-Effectiveness Analyses: Lisocabtagene Maraleucel (Liso-Cel) Versus Standard of Care (SOC) in Second-Line Relapsed or Refractory Large B-Cell Lymphoma
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.2137
https://www.valueinhealthjournal.com/article/S1098-3015(23)05267-1/fulltext
Title :
MSR78 Use of External Control Data to Adjust for Treatment Switching in Cost-Effectiveness Analyses: Lisocabtagene Maraleucel (Liso-Cel) Versus Standard of Care (SOC) in Second-Line Relapsed or Refractory Large B-Cell Lymphoma
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)05267-1&doi=10.1016/j.jval.2023.09.2137
First page :
Section Title :
Open access? :
No
Section Order :
11580